Obalon Therapeutics Inc (NASDAQ:OBLN) has been assigned a $17.00 price target by analysts at Canaccord Genuity in a report released on Friday. The firm currently has a a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 57.41% from the stock’s previous close.

Several other brokerages have also recently issued reports on OBLN. Stifel Nicolaus assumed coverage on shares of Obalon Therapeutics in a report on Monday, October 31st. They set a “buy” rating and a $18.00 target price for the company. BTIG Research assumed coverage on shares of Obalon Therapeutics in a report on Monday, October 31st. They set a “buy” rating and a $20.00 target price for the company.

Shares of Obalon Therapeutics (NASDAQ:OBLN) opened at 10.80 on Friday. The firm has a 50-day moving average of $12.31 and a 200 day moving average of $12.31. Obalon Therapeutics has a 52 week low of $8.27 and a 52 week high of $15.88. The stock’s market cap is $6.26 million.

In other news, Director Kim P. Kamdar acquired 13,400 shares of the business’s stock in a transaction on Wednesday, October 12th. The stock was bought at an average price of $15.00 per share, with a total value of $201,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Obalon Therapeutics Company Profile

Obalon Therapeutics, Inc is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

5 Day Chart for NASDAQ:OBLN

Receive News & Stock Ratings for Obalon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics Inc and related stocks with our FREE daily email newsletter.